28/07/2025
Lower doses of enoxaparin(clexane) is more effective in lowering pregnancy loss rates in women with recurrent spontaneous abortion than higher doses .A recent study says:
Recurrent spontaneous abortion (RSA) is a severe concern for women's reproductive health, with an incidence of 1% to 5%.(1)
Low molecular weight heparin (LMWH)is widely recognized as an effective treatment for RSA caused by antiphospholipid syndrome (APS), post-thrombotic syndrome (PTS), autoimmune diseases, and other conditions.(2)
Recent studies have shown that LMWH, aside from its anticoagulant effects, offers immunomodulatory and other benefits. These benefits include inhibiting the immune response triggered by antiphospholipid antibodies , promoting trophoblast proliferation , invasion and differentiation, preventing trophoblast apoptosis, protecting vascular endothelium, and enhancing placental formation.(3,4)
There has been an increasing trend among clinicians that increasing the doses of clexane might be more effective in improving live birth rates and lowering prenancy loss rate (LBR). However, the current evidence antagonizes that belief.
A recent systematic review and meta-analysis (level I evidence & level A recommendation) , published by American Journal of Of Obstetrics & Gynecology in February 2025 concluded that both the 20mg and 40mg doses of enoxaparin were effective in increasing live birth rates and lowering pregnancy loss risk, among women with recurrent pregnancy loss . The study emphasized that the 20mg dose has shown superior efficacy over the 40mg dose. (5)
The research added that enoxaparin beside significantly improving live birth rates , also reduces the risks of pre-eclampsia, preterm delivery, and pregnancy loss.
The research data were collected from 22 randomized controlled trials, encompassing 4,773 participants.
It seems that increasing the doses of clexane during pregnancy as a trial to improve live birth rates and reducing pregnancy loss risk might only add more economic suffering together with higher risks of maternal side effects from the drug.
Mohamed Ali Abdelkader(MD)
References:
1) Genovese HG, McQueen DB. The prevalence of sporadic and recurrent pregnancy loss. Fertil Steril. 2023 Nov;120(5):934-936
2) Berker B, Taşkın S, Kahraman K.
The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study.Fertility and Sterility, Volume 95, Issue 7, June 2011, Pages e29
3) Brenner B. Enoxaparin use in pregnancy: state of the art. Womens Health (Lond). 2007 Jan;3(1):9-14.
4) Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, Le Gal G, Debarge V, Lecomte F, Denoual-Ziad C, Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood. 2015 Apr 2;125(14):2200-5.
5)Huang W, Yu Y, Chen L, Tang X, Fang X, Ou X, Du X. Comparative effectiveness of low molecular weight heparin on live birth for recurrent spontaneous abortion: systematic review and network meta-analysis. Am J Obstet Gynecol MFM. 2025 Feb;7(2):101572.